New Delhi, Jan. 19 -- The Delhi High Court's division bench on Monday reserved its verdict on Danish drugmaker Novo Nordisk's appeal against a single-judge order that allowed Dr Reddy's Laboratories to manufacture semaglutide in India and export it to countries where the blockbuster diabetes and weight-loss drug is not under patent protection.

A bench of Justice C. Hari Shankar and Justice Om Prakash Shukla heard arguments from both sides.

Semaglutide is used to treat type-2 diabetes and obesity. It works by mimicking the GLP-1 hormone to control blood sugar, suppress appetite and promote weight loss.

Novo Nordisk markets it as Ozempic for diabetes and Wegovy for weight management. The drug is currently among the world's most valuable ...